Inflammatory Myofibroblastic Tumor of Extremities / 대한골관절종양학회지
The Journal of the Korean Bone and Joint Tumor Society
;
: 14-19, 2013.
Artículo
en Coreano
| WPRIM
| ID: wpr-88311
ABSTRACT
PURPOSE:
We analyzed the oncologic characteristics and outcome of patients with inflammatory myofibroblastic tumor of extremities. MATERIALS ANDMETHODS:
Among the soft tissue tumor patients who were treated between 1999 and 2012, 5 patients who were pathologically confirmed as the inflammatory myofibroblastic tumor of extremities were analyzed retrospectively.RESULTS:
There were 1 man and 4 women with mean age of 44 years (37-55 years). The average follow up was 34.6 months (8-87 months). All patients underwent surgical treatment. Only 1 patient had wide resection margin and remaining 4 had marginal (3) or intralesional (1) resection margin. All of 4 patients without wide resection margin developed local recurrence at 10.3 months (8-19 months). Malignant transformation to fibrosarcoma was occurred in 2 patients who developed local recurrence, and 1 patient developed multiple metastases to lung, liver and lymph nodes and expired at 37 months. Three of 5 patients had tumor location abutted to or invasion to major arteries and 1 patient had tumor invading sciatic nerve.CONCLUSION:
It is observed that inflammatory myofibroblastic tumor of extremities is usually located near the major neurovascular structure. Wide resection should be considered as the initial surgical treatment because this tumor showed a high local recurrence rate and possibility of malignant transformation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Arterias
/
Recurrencia
/
Estudios de Seguimiento
/
Extremidades
/
Miofibroblastos
/
Fibrosarcoma
/
Hígado
/
Pulmón
/
Ganglios Linfáticos
/
Metástasis de la Neoplasia
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Femenino
/
Humanos
Idioma:
Coreano
Revista:
The Journal of the Korean Bone and Joint Tumor Society
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS